Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

May 29, 2019

Primary Completion Date

June 30, 2027

Study Completion Date

October 21, 2027

Conditions
Urothelial Carcinoma
Interventions
DRUG

Tislelizumab

200 mg administered Intravenously (IV) as specified in the treatment arm

DRUG

Placebo

Tislelizumab placebo to match

DRUG

Cisplatin

70 mg/m2 administered IV as specified in the treatment arm

DRUG

Gemcitabine Hydrochloride

1000 mg/m2 administered IV as specified in the treatment arm

DRUG

Carboplatin

Area Under the Curve (AUC) 4.5 administered IV as specified in the treatment arm

Trial Locations (46)

204

COMPLETED

Keelung Chang Gung Memorial Hospital and Loves Lake Branch, Anle Dist

704

COMPLETED

National Cheng Kung University Hospital, North Dist

11217

COMPLETED

Taipei Veterans General Hospital, Beitou Dist

33305

COMPLETED

Linkou Chang Gung Memorial Hospital, Guishan Dist

100000

ACTIVE_NOT_RECRUITING

Peking University Third Hospital, Beijing

100034

RECRUITING

Peking University First Hospital, Beijing

100050

RECRUITING

Beijing Friendship Hospital, Capital Medical University, Beijing

100071

RECRUITING

Fifth Medical Center of Pla General Hospital, Beijing

100142

RECRUITING

Beijing Cancer Hospital, Beijing

100225

COMPLETED

National Taiwan University Hospital, Zhongzheng Dist

100730

COMPLETED

Peking Union Medical College Hospital, Beijing

100853

COMPLETED

Chinese Pla General Hospital, Beijing

110042

ACTIVE_NOT_RECRUITING

Liaoning Cancer Hospital and Institute, Shenyang

130021

RECRUITING

The First Hospital of Jilin University, Changchun

150000

ACTIVE_NOT_RECRUITING

Harbin Medical University Cancer Hospital, Harbin

200000

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

200025

ACTIVE_NOT_RECRUITING

Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai

200032

ACTIVE_NOT_RECRUITING

Affiliated Zhongshan Hospital of Fudan University, Shanghai

200040

COMPLETED

Huadong Hospital Affiliated to Fudan University, Shanghai

COMPLETED

Huashan Hospital Affiliated to Fudan University, Shanghai

200433

COMPLETED

Shanghai Changhai Hospital, Shanghai

210008

ACTIVE_NOT_RECRUITING

Jiangsu Province Cancer Hospital, Nanjing

RECRUITING

Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School, Nanjing

230000

ACTIVE_NOT_RECRUITING

Anhui Provincial Hospital, Hefei

300000

RECRUITING

The Second Affiliated Hospital of Tianjin Medical University, Tianjin

310014

RECRUITING

Zhejiang Provincial Peoples Hospital, Hangzhou

310022

COMPLETED

Zhejiang Cancer Hospital, Hangzhou

315010

COMPLETED

Ningbo First Hospital, Ningbo

325000

RECRUITING

The First Provincial Wenzhou Hospital of Zhejiang, Wenzhou

330006

ACTIVE_NOT_RECRUITING

The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang

350005

RECRUITING

The First Affiliated Hospital of Fujian Medical University, Fuzhou

361003

RECRUITING

The First Affiliated Hospital of Xiamen University, Xiamen

362001

RECRUITING

The Second Affiliated Hospital of Fujian Medical University, Quanzhou

400030

RECRUITING

Chongqing Cancer Hospital, Chongqing

400038

RECRUITING

Southwest Hospital, Chongqing

410008

COMPLETED

Xiangya Hospital of Central South University, Changsha

430022

RECRUITING

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

430030

ACTIVE_NOT_RECRUITING

Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan

430079

ACTIVE_NOT_RECRUITING

Hubei Cancer Hospital, Wuhan

510000

RECRUITING

Zhujiang Hospital of Southern Medical University, Guangzhou

510245

RECRUITING

Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou

610041

RECRUITING

West China Hospital, Sichuan University, Chengdu

610071

ACTIVE_NOT_RECRUITING

Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu

650100

ACTIVE_NOT_RECRUITING

Yunnan Cancer Hospital, Kunming

710004

RECRUITING

The Second Affiliated Hospital of Xian Jiaotong University, Xi'an

830000

RECRUITING

Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT03967977 - Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma | Biotech Hunter | Biotech Hunter